Cargando…

Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease

Worldwide, Alzheimer’s disease (AD) is the most common age-related neurodegenerative disease and is characterized by unique pathological hallmarks in the brain, including plaques composed of amyloid β-protein (Aβ) and neurofibrillary tangles of tau protein. Genetic studies, biochemical data, and ani...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ono, Kenjiro, Tsuji, Mayumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037706/ https://www.ncbi.nlm.nih.gov/pubmed/32023927 http://dx.doi.org/10.3390/ijms21030952

Ejemplares similares

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
por: Lannfelt, Lars, et al.
Publicado: (2014)

A possible mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer’s disease
por: Chen, Zu-Lin, et al.
Publicado: (2023)

Amyloid-β Protofibrils: Size, Morphology and Synaptotoxicity of an Engineered Mimic
por: Dubnovitsky, Anatoly, et al.
Publicado: (2013)

Mechanisms of U87 Astrocytoma Cell Uptake and Trafficking of Monomeric versus Protofibril Alzheimer’s Disease Amyloid-β Proteins
por: Li, Yali, et al.
Publicado: (2014)

Sensitive detection of Aβ protofibrils by proximity ligation - relevance for Alzheimer's disease
por: Kamali-Moghaddam, Masood, et al.
Publicado: (2010)

Pharmacological Potential of Cilostazol for Alzheimer’s Disease
por: Ono, Kenjiro, et al.
Publicado: (2019)

Correction: Amyloid-β Protofibrils: Size, Morphology and Synaptotoxicity of an Engineered Mimic
por: Dubnovitsky, Anatoly, et al.
Publicado: (2013)

Atomic resolution dynamics on the surface of amyloid β protofibrils probed by solution NMR
por: Fawzi, Nicolas L., et al.
Publicado: (2011)

Dynamics of protofibril elongation and association involved in Aβ42 peptide aggregation in Alzheimer’s disease
por: Ghosh, Preetam, et al.
Publicado: (2010)

Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice
por: Martins, Ivo Cristiano, et al.
Publicado: (2008)

Amyloid Beta Annular Protofibrils in Cell Processes and Synapses Accumulate with Aging and Alzheimer-Associated Genetic Modification
por: Kokubo, Hideko, et al.
Publicado: (2009)

Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ(42) Protofibrils in Alzheimer’s Disease
por: Söllvander, Sofia, et al.
Publicado: (2015)

Amyloid Oligomers and Protofibrils, but Not Filaments, Self-Replicate from Native Lysozyme
por: Mulaj, Mentor, et al.
Publicado: (2014)

Formation of amyloid loops in brain tissues is controlled by the flexibility of protofibril chains
por: Miller, Alyssa, et al.
Publicado: (2023)

Partial Destabilization of Amyloid-β Protofibril by Methionine Photo-Oxidation: A Molecular Dynamic Simulation Study
por: Maghsoodi, Fahimeh, et al.
Publicado: (2023)

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
por: Logovinsky, Veronika, et al.
Publicado: (2016)

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
por: Song, Chenghuan, et al.
Publicado: (2022)

Protofibril–Fibril Interactions Inhibit Amyloid Fibril Assembly by Obstructing Secondary Nucleation
por: Hasecke, Filip, et al.
Publicado: (2020)

Considerably Unfolded Transthyretin Monomers Preceed and Exchange with Dynamically Structured Amyloid Protofibrils
por: Groenning, Minna, et al.
Publicado: (2015)

Conformation‐specific antibodies against multiple amyloid protofibril species from a single amyloid immunogen
por: Bonito‐Oliva, Alessandra, et al.
Publicado: (2019)

Increased Release of Apolipoprotein E in Extracellular Vesicles Following Amyloid-β Protofibril Exposure of Neuroglial Co-Cultures
por: Nikitidou, Elisabeth, et al.
Publicado: (2017)

Interacting Models of Amyloid-β and Tau Proteins: An Approach to Identify Drug Targets in Alzheimer’s Disease
por: Priya, Khadgawat, et al.
Publicado: (2021)

Editorial: Targets for Disease-Modifying Therapies in Alzheimer’s Disease, Including Amyloid β and Tau Protein
por: Parums, Dinah V.
Publicado: (2021)

Distinct Annular Oligomers Captured along the Assembly and Disassembly Pathways of Transthyretin Amyloid Protofibrils
por: Pires, Ricardo H., et al.
Publicado: (2012)

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2023)

Insight Into Seeded Tau Fibril Growth From Molecular Dynamics Simulation of the Alzheimer’s Disease Protofibril Core
por: Leonard, Cass, et al.
Publicado: (2021)

Amyloid-β: Structure, Function, and Pathophysiological Significance in Neurodegenerative Diseases
por: Saito, Satoshi, et al.
Publicado: (2022)

β-Amyloid Degradation and Alzheimer's Disease
por: Wang, Deng-Shun, et al.
Publicado: (2006)

Mitochondria, Amyloid β, and Alzheimer's Disease
por: Readnower, Ryan D., et al.
Publicado: (2011)

The Amyloid-β Pathway in Alzheimer’s Disease
por: Hampel, Harald, et al.
Publicado: (2021)

Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease
por: Mashal, Yara, et al.
Publicado: (2022)

The effect of α-tocopherol, α- and γ-tocotrienols on amyloid-β aggregation and disaggregation in vitro
por: Ibrahim, Nor Faeizah, et al.
Publicado: (2021)

The Mechanisms of the Roles of α-Synuclein, Amyloid-β, and Tau Protein in the Lewy Body Diseases: Pathogenesis, Early Detection, and Therapeutics
por: Noguchi-Shinohara, Moeko, et al.
Publicado: (2023)

Disease-Modifying Effects of Non-Invasive Electroceuticals on β-Amyloid Plaques and Tau Tangles for Alzheimer’s Disease
por: Bok, Junsoo, et al.
Publicado: (2022)

Amyloid β-protein oligomers and Alzheimer’s disease
por: Hayden, Eric Y, et al.
Publicado: (2013)

Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?
por: Castillo-Carranza, Diana L, et al.
Publicado: (2013)

Aluminium Binding to Modified Amyloid-β Peptides: Implications for Alzheimer’s Disease
por: Mocanu, Cosmin Stefan, et al.
Publicado: (2020)

Evidence for impaired amyloid β clearance in Alzheimer's disease
por: Wildsmith, Kristin R, et al.
Publicado: (2013)

Metabolism of amyloid β peptide and pathogenesis of Alzheimer’s disease
por: SAIDO, Takaomi C.
Publicado: (2013)

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
por: Swanson, Chad J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jdvpl5ov63v4pfjqu7ao0o96p5